JP2018537433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537433A5 JP2018537433A5 JP2018522787A JP2018522787A JP2018537433A5 JP 2018537433 A5 JP2018537433 A5 JP 2018537433A5 JP 2018522787 A JP2018522787 A JP 2018522787A JP 2018522787 A JP2018522787 A JP 2018522787A JP 2018537433 A5 JP2018537433 A5 JP 2018537433A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- seq
- combination
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083194A JP2021120405A (ja) | 2015-11-03 | 2021-05-17 | Ｃｄ２００阻害剤及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250376P | 2015-11-03 | 2015-11-03 | |
| US62/250,376 | 2015-11-03 | ||
| PCT/US2016/060164 WO2017079335A1 (en) | 2015-11-03 | 2016-11-02 | Cd200 inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083194A Division JP2021120405A (ja) | 2015-11-03 | 2021-05-17 | Ｃｄ２００阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537433A JP2018537433A (ja) | 2018-12-20 |
| JP2018537433A5 true JP2018537433A5 (enExample) | 2019-11-28 |
| JP6902185B2 JP6902185B2 (ja) | 2021-07-14 |
Family
ID=58662756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522787A Active JP6902185B2 (ja) | 2015-11-03 | 2016-11-02 | Ｃｄ２００阻害剤及びその使用方法 |
| JP2021083194A Pending JP2021120405A (ja) | 2015-11-03 | 2021-05-17 | Ｃｄ２００阻害剤及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083194A Pending JP2021120405A (ja) | 2015-11-03 | 2021-05-17 | Ｃｄ２００阻害剤及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10888609B2 (enExample) |
| EP (2) | EP3370763B1 (enExample) |
| JP (2) | JP6902185B2 (enExample) |
| AU (1) | AU2016349897B2 (enExample) |
| CA (1) | CA3004048A1 (enExample) |
| WO (1) | WO2017079335A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| WO2019084682A1 (en) | 2017-10-30 | 2019-05-09 | Mcmaster University | Methods for the diagnosis and treatment of endometriosis |
| EP3911357A1 (en) * | 2019-01-14 | 2021-11-24 | Regents of the University of Minnesota | Cd200ar ligands for cancer immunotherapy |
| CN118420719B (zh) * | 2023-04-10 | 2025-06-10 | 湖南中晟全肽生物科技股份有限公司 | 人cd200受体的拮抗剂结合多肽分子及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US5744585A (en) | 1995-03-16 | 1998-04-28 | Medenica; Rajko D. | Human monoclonal antibody against lung carcinoma |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| DK1032662T3 (da) * | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| AU2333802A (en) * | 2000-11-22 | 2002-06-03 | Transplantation Technologies I | Truncated cd200 |
| NZ599035A (en) | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| WO2012048190A1 (en) | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US9737598B2 (en) | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
-
2016
- 2016-11-02 US US15/773,527 patent/US10888609B2/en active Active
- 2016-11-02 EP EP16862903.8A patent/EP3370763B1/en active Active
- 2016-11-02 EP EP24161083.1A patent/EP4410376A3/en active Pending
- 2016-11-02 JP JP2018522787A patent/JP6902185B2/ja active Active
- 2016-11-02 AU AU2016349897A patent/AU2016349897B2/en active Active
- 2016-11-02 WO PCT/US2016/060164 patent/WO2017079335A1/en not_active Ceased
- 2016-11-02 CA CA3004048A patent/CA3004048A1/en active Pending
-
2020
- 2020-12-07 US US17/114,193 patent/US11826408B2/en active Active
-
2021
- 2021-05-17 JP JP2021083194A patent/JP2021120405A/ja active Pending
-
2022
- 2022-06-21 US US17/845,916 patent/US11666645B2/en active Active
-
2023
- 2023-10-03 US US18/376,297 patent/US20240050543A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021058197A5 (enExample) | ||
| JP2018537433A5 (enExample) | ||
| RU2017126601A (ru) | Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras | |
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2019088286A5 (enExample) | ||
| JP2020510624A5 (enExample) | ||
| RU2016123370A (ru) | Ингибитор контрольных точек и цельноклеточная микробактерия для использования при лечении онкологического заболевания | |
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| JP2011103891A5 (enExample) | ||
| JP2018537975A5 (enExample) | ||
| JP2017521486A5 (enExample) | ||
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Barmettler et al. | Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer | |
| CN103992382A (zh) | 一种靶向eps8与egfr结合的短肽及其应用 | |
| CN115869325A (zh) | 化合物用于制备治疗kras突变癌症患者的药物的用途 | |
| O. Laukkanen et al. | Gastrin-releasing peptide receptor targeting in cancer treatment: emerging signaling networks and therapeutic applications | |
| JP2008500277A5 (enExample) | ||
| JP2018100243A5 (enExample) | ||
| CN101208106B (zh) | 癌症治疗剂 | |
| JP2019519536A5 (enExample) | ||
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| AU2012281131B2 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
| JPWO2019196764A5 (enExample) | ||
| CN115698076A (zh) | 用于治疗肿瘤的药物 |